The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Aguilar Mahecha, Adriana ^a   Kuzyk, Michael A ^b   Domanski, Dominik ^b   Borchers, Christoph H ^b,c   Basik, Mark ^a  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

^c UNIVERSITY OF VICTORIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; EOTAXIN; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR BB; RANTES; TUMOR NECROSIS FACTOR; VASCULOTROPIN; PLASMA PROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CENTRIFUGATION; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; LABORATORY TEST; LOW TEMPERATURE; MALE; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING MASS SPECTROMETRY; NORMAL HUMAN; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN STABILITY; PROTEOMICS; THROMBOCYTE ACTIVATION; UPREGULATION; BLOOD; INSTRUMENTATION; METHODOLOGY; MIDDLE AGED; STATISTICAL MODEL;

ADULT; BIOLOGICAL MARKERS; BLOOD PROTEINS; BLOOD SPECIMEN COLLECTION; CYTOKINES; FEMALE; HUMANS; LINEAR MODELS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEOMICS;

EID: 84862012968     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038290     Document Type: Article

References (29)

1. Hanash SM, Baik CS, Kallioniemi O, (2011) Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nature Reviews of Clinical Oncology 8: 142-150.
2. Anderson NL, Anderson NG, (2002) The human plasma proteome:history, character, and diagnostic prospects. Molecular and Cellular Proteomics 1: 845-867.
3. Polanski M, Anderson NL, (2007) A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights. 2007 Feb 7;1:1-48. Biomark Insights 7: 1-48.
4. Rai AJ, Vitzthum F, (2006) Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Reviews of Proteomics 3: 409-426.
5. Rifai N, Gillette MA, Carr SA, (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nature Biotechnology 24: 971-983.
6. Jackson DH, Banks RE, (2010) Banking of clinical samples for proteomic biomarker studies: a consideration of logistical issues with a focus on pre-analytical variation. Proteomics Clinical Applications 4: 250-270.
7. Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, et al. (2005) HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics 5: 3262-3277.
8. Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, et al. (2009) Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. Journal of Proteome Research 8: 113-117.
9. Macey M, Azam U, McCarthy D, Webb L, Chapman ES, et al. (2002) Evaluation of the anticoagulants EDTA and citrate, theophylline, adenosine, and dipyridamole (CTAD) for assessing platelet activation on the ADVIA 120 hematology system. Clin Chem 48: 891-899.
10. Proc JL, Kuzyk MA, Hardie DB, Yang J, Smith DS, et al. (2010) A Quantitative Study of the Effects of Chaotropic Agents, Surfactants, and Solvents on the Digestion Efficiency of Human Plasma Proteins by Trypsin. Journal of Proteome Research 9: 5422-5437.
11. Kuzyk MA, Smith D, Yang J, Cross TJ, Jackson AM, et al. (2009) MRM-based, Multiplexed, Absolute Quantitation of 45 proteins in human plasma. Molecular and Cellular Proteomics 8: 1860-1877.
12. Fu Q, Zhu J, Van Eyk JE, (2010) Comparison of multiplex immunoassay platforms. Clinical Chemistry 56: 314-318.
13. Hsu J, (1996) Multiple Comparisons: Theory and Methods. London Chapman & Hall.
14. Qureshi AH, Chaoji V, Maiguel D, Faridi MH, Barth CJ, et al. (2009) Proteomic and phospho-proteomic profile of human platelets in basal, resting state: insights into integrin signaling. PLoSOne 4: e7627.
15. Ahnadi CE, Sabrinah Chapman E, Lépine M, Okrongly D, Pujol-Moix N, et al. (2003) Assessment of platelet activation in several different anticoagulants by the Advia 120 Hematology System, fluorescence flow cytometry, and electron microscopy. Thrombosis and Haemostasis 90: 940-948.
16. Rodriguez H, Rivers R, Kinsinger C, Mesri M, Hiltke T, et al. (2010) Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective. Proteomics Clinical Applications 4: 904-914.
17. de Jager, W, Bourcier, K, Rijkers, GT, Prakken, BJ, Seyfert-Margolis, V, (2009) Prerequisites for cytokine measurements in clinical trials with multiplex immunoassay BMC Immunol 10: 52.
18. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, et al. (2005) Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clinical Chemistry 51: 1637-1649.
19. Tammen H, Schulte I, Hess R, Menzel C, Kellmann M, et al. (2005) Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5: 3414-3422.
20. Yi J, Kim C, Gelfand CA, (2007) Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. Journal of Proteome Research 6: 1768-1781.
21. Randall SA, McKay MJ, Molloy MP, (2010) Evaluation of blood collection tubes using selected reaction monitoring MS: implications for proteomic biomarker studies. Proteomics 10: 2050-2056.
22. Wildes D, Wells JA, (2010) Sampling the N-terminal proteome of human blood. Proceedings of the National Academy of Sciences of the United States of America 107: 4561-4566.
23. Yi J, Liu Z, Craft D, O'Mullan P, Ju G, et al. (2008) Intrinsic peptidase activity causes asequential multi-step reaction (SMSR) in digestion of human plasma peptides. Journal of Proteome Research 7: 5112-5118.
24. Oliver AE, Tablin F, Walker NJ, Crowe JH, (1999) The internal calcium concentration of human platelets increases during chilling. Biochimica et Biophysica Acta 1416: 349-360.
25. Winokur R, Hartwig J, (1995) Mechanism of shape change in chilled human platelets. Blood 85: 1796-1804.
26. Zimmermann R, Koenig J, Zingsem J, Weisbach V, Strasser E, et al. (2005) Zimmermann R, Koenig J, Zingsem J, Weisbach V, Strasser E, Ringwald J, Eckstein R. Effect of specimen anticoagulation on the measurement of circulating platelet-derived growth factors. Clin Chem. 2005 Dec;51(12): 2365-8. Clinical Chemistry 51: 2365-2368.
27. Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, et al. (1998) Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. British Journal of Cancer 77: 956-964.
28. Zimmermann R, Ringwald J, Eckstein R, (2009) EDTA plasma is unsuitable for in vivo determinations of platelet-derived angiogenic cytokines. Journal of Immunological Methods 347: 91-92.
29. Blair P, Flaumenhaft R, (2009) Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009 Jul;23(4): 177-89. Epub 2009 May 17. Blood Reviews 23: 177-189.